Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
A | 0.700 | GeneticVariation | GWASCAT | Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. | 30718926 | 2019 |
|||
|
0.020 | GeneticVariation | BEFREE | Yet, there was no significant association of GIPR rs1800437 or GLP-1R rs367543060 with T2DM risk. | 28744963 | 2017 |
||||
|
0.020 | GeneticVariation | BEFREE | A genetic link between the T149M variant and increased susceptibility to type 2 diabetes remains to be established. | 15975668 | 2005 |
||||
|
0.010 | GeneticVariation | BEFREE | The consistent large clinical impact of rs10305420 on glycemic response and weight response to exenatide makes the variant a strong candidate biomarker for precision medicine, particularly among overweight patients with Type 2 diabetes. | 30883264 | 2019 |
||||
|
0.010 | GeneticVariation | BEFREE | A low-frequency missense variant (Ala316Thr; rs10305492) in the gene encoding glucagon-like peptide-1 receptor (GLP1R), the target of GLP1R agonists, was associated with lower fasting glucose and T2D risk, consistent with GLP1R agonist therapies. | 27252175 | 2016 |
||||
|
0.010 | GeneticVariation | BEFREE | We aimed to investigate whether genetic variations in glucagon-like peptide (GLP-1) receptor are associated with responses to DPP-4 inhibitors in patients with type 2 diabetes.Genetic variations of rs3765467 in GLP-1 receptor were explored in 246 patients with type 2 diabetes who received DPP-4 inhibitors treatment for 24 weeks in addition to previous medication. | 27858848 | 2016 |
||||
|
0.010 | GeneticVariation | BEFREE | Our cross-sectional study revealed an association between the rs6923761 GLP-1 receptor polymorphism (A allele carriers) and basal GLP-1 levels in naïve patients with diabetes mellitus type 2. | 25200998 | 2015 |